Premium
P3‐139: CHARACTERISING THE AUSTRALIAN IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING COHORT AT 36 AND 54 MONTHS
Author(s) -
Ames David,
Ellis Kathryn A.,
Fowler Chris,
RaineySmith Stephanie Ruth
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1228
Subject(s) - dementia , medicine , cohort , biomarker , cognitive decline , ageing , prospective cohort study , gerontology , disease , biochemistry , chemistry
different levels of instrumental ADL (IADL) impairment at baseline, from 6.6 6 2.8 years (IADL score, 8-12) to 5.0 6 2.5 years (IADL score, 2131) (P< 0.001). The time from AD diagnosis to death also differed between patients receiving antihypertensive/cardiac therapy (no/yes, 6.16 2.7 vs 5.3 6 2.8 years; P< 0.001), antidiabetics (no/yes, 5.86 2.8 vs 4.16 2.4 years; P< 0.001), nonsteroidal anti-inflammatory drugs (NSAIDs)/acetylsalicylic acid; no/yes, 6.0 6 2.8 vs 5.2 6 2.6 years;P < 0.001), and antipsychotics (no/yes, 5.8 6 2.8 vs 4.7 6 2.5 years; P 1⁄4 0.020). IADL score at baseline and antihypertensive/cardiac therapy, antidiabetics, and antipsychotics were independent predictors of survival after AD diagnosis in a general linear model, after controlling for sex, age, and cognitive ability. Basic ADL, number of medications, and specific concomitant medications (lipid-lowering agents, NSAIDs/acetylsalicylic acid, antidepressants, and anxiolytics/sedatives/hypnotics) at baseline were not significant predictors. Conclusions: IADL, but not basic ADL, was an important predictor that should be considered by clinicians and community-based services when estimating AD prognosis. Antidiabetic therapy was a strong risk factor for reduction in life expectancy.